Belatacept

Selective T Cell Costimulation Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Belatacept is a drug in the Selective T Cell Costimulation Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2011. Its mechanism of action is classified as CD80-directed Antibody Interactions and CD86-directed Antibody Interactions. DrugCentral lists 2 molecular targets, including CD80 and CD86. Recorded indications include Renal transplant rejection.

• Drug class: Selective T Cell Costimulation Blocker.
• Mechanism of action: CD80-directed Antibody Interactions; CD86-directed Antibody Interactions.
• Molecular targets: CD80 and CD86 (2 listed in DrugCentral).
• Indications: Renal transplant rejection.
• ATC code: L04AA28 (Selective immunosuppressants).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Renal transplant rejection

Mechanism & targets

• Mechanism of action (MoA): CD80-directed Antibody Interactions; CD86-directed Antibody Interactions
• Established pharmacologic class: Selective T Cell Costimulation Blocker

Molecular targets (2)

Target	Gene	Action	Activity
T-lymphocyte activation antigen CD80	CD80	inhibitor	—
T-lymphocyte activation antigen CD86	CD86	inhibitor	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2011-06-17	EMA	—	—
2011-06-15	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
L04AA28	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Kidney transplant rejection	822.4
Transplant rejection	785.4
Product storage error	594.2
Cytomegalovirus infection	438.7
Post transplant lymphoproliferative disorder	298.2
Thrombotic microangiopathy	259.3
Polyomavirus viraemia	257.9
Product preparation error	256.7
Product preparation issue	227.9
Cytomegalovirus viraemia	203.6
Graft loss	194.6
Pneumocystis jirovecii pneumonia	181.1

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 706808-37-9
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Belatacept used for?

DrugCentral lists the following indications for Belatacept: Renal transplant rejection.

How does Belatacept work?

Belatacept is classified as CD80-directed Antibody Interactions and CD86-directed Antibody Interactions; its molecular targets in DrugCentral include CD80 (inhibitor) and CD86 (inhibitor).

When was Belatacept first approved?

Belatacept was first approved by the FDA in 2011.

What drug class does Belatacept belong to?

Belatacept is in the Selective T Cell Costimulation Blocker class.

Sources

• DrugCentral drug card 5091 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1742990 — compound record and bioactivity
• DrugBank DB06681 — drug record
• FDA UNII E3B2GI648A — substance identity
• DailyMed: FDA labels for Belatacept — current prescribing information (label search)
• UniProt P33681 (CD80) — target protein
• UniProt P42081 (CD86) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.